Moderna’s customized mRNA cancer vaccine intismeran cleared a key Phase 3 bar at ESMO, cutting the risk of recurrence or death versus pembrolizumab alone. The result renewed momentum for neoantigen and mRNA-based therapeutic vaccines as an approach that can be tested head-to-head in larger, definitive programs. Executives framed the key next step as regulatory submission and broader development beyond melanoma, with teams positioned to adapt manufacturing and clinical trial strategy for faster access. The Phase 3 outcome also sets a higher bar for future vaccine trials aiming to demonstrate survival-grade benefit rather than immunogenicity endpoints. For oncology product planning, the data reinforce that “personalized” cancer vaccines are moving from proof-of-concept to late-stage evidence—while highlighting the operational challenge of scaling individualized therapies for global patient populations.